GNPX · Insider Trading
Genprex, Inc. Common Stock
Every open-market purchase and sale reported by GNPX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-15 | Brent M Longnecker | Director | Sell | −18 | −$22 |
| 2026-02-27 | Mark Stanley Berger | Chief Medical Officer | F | −7,168 | −$14.34K |
| 2026-02-27 | Ryan M. Confer | President, CEO and CFO | F | −9,330 | −$18.66K |
| 2025-12-23 | Brent M Longnecker | Director | A | +9,000 | — |
| 2025-12-23 | William R Wilson Jr. | Director | A | +9,000 | — |
| 2025-12-23 | Toscano Jose Antonio Moreno | Director | A | +9,000 | — |
| 2025-12-23 | Mark Stanley Berger | Chief Medical Officer | A | +28,500 | — |
| 2025-12-23 | Ryan M. Confer | President, CEO and CFO | A | +45,000 | — |
| 2025-07-01 | Mark Stanley Berger | Chief Medical Officer | F | −4,500 | −$1.03K |
| 2025-07-01 | Ryan M. Confer | President, CEO and CFO | F | −5,775 | −$1.32K |
| 2025-02-19 | Mark Stanley Berger | Chief Medical Officer | F | −585 | −$240 |
| 2025-02-19 | Ryan M. Confer | President, CEO and CFO | F | −395 | −$162 |
| 2024-12-06 | Ryan M. Confer | President, CEO and CFO | A | +29,375 | — |
| 2024-12-06 | Mark Stanley Berger | Chief Medical Officer | A | +18,250 | — |
| 2024-12-06 | William R Wilson Jr. | Director | A | +4,750 | — |
| 2024-12-06 | Toscano Jose Antonio Moreno | Director | A | +4,750 | — |
| 2024-12-06 | Brent M Longnecker | Director | A | +4,750 | — |
| 2024-02-21 | Mark Stanley Berger | Chief Medical Officer | F | −1,319 | −$5.80K |
| 2024-02-21 | Ryan M. Confer | Chief Financial Officer | F | −1,126 | −$4.95K |
| 2024-02-21 | John Rodney Varner | Chairman, President and CEO | F | −2,642 | −$11.62K |
| 2023-06-29 | Brent M Longnecker | Director | A | +123,795 | — |
| 2023-06-29 | William R Wilson Jr. | Director | A | +123,795 | — |
| 2023-06-29 | Toscano Jose Antonio Moreno | Director | A | +123,795 | — |
| 2023-04-24 | Catherine M Vaczy | EVP GC Chief Strategy Officer | Buy | +20,000 | +$21.48K |
| 2023-04-24 | John Rodney Varner | Chairman, President and CEO | Buy | +19,000 | +$20.05K |
| 2023-02-22 | Catherine M Vaczy | EVP GC Chief Strategy Officer | A | +245,000 | — |
| 2023-02-22 | Hermant Kumar | Chief Mfgr & Tech Officer | A | +200,000 | — |
| 2023-02-22 | John Rodney Varner | President & CEO | A | +625,000 | — |
| 2023-02-22 | Ryan M. Confer | Chief Financial Officer | A | +245,000 | — |
| 2023-02-22 | Mark Stanley Berger | Chief Medical Officer | A | +245,000 | — |
| 2022-08-01 | Ryan M. Confer | Chief Financial Officer | M | +116,973 | +$1.75K |
| 2022-06-27 | William R Wilson Jr. | Director | A | +83,368 deriv. | — |
| 2022-06-27 | Hermant Kumar | Chief Mfgr & Tech Officer | A | +75,000 deriv. | — |
| 2022-06-27 | Brent M Longnecker | Director | A | +83,368 deriv. | — |
| 2022-06-27 | Toscano Jose Antonio Moreno | Director | A | +83,368 deriv. | — |
| 2022-02-08 | Hermant Kumar | Chief Mfgr & Tech Officer | A | +54,312 deriv. | — |
| 2022-02-08 | John Rodney Varner | President & CEO | A | +1,062,250 deriv. | — |
| 2022-02-08 | Mark Stanley Berger | Chief Medical Officer | A | +98,750 deriv. | — |
| 2022-02-08 | Catherine M Vaczy | EVP GC Chief Strategy Officer | A | +325,000 deriv. | — |
| 2022-02-08 | Ryan M. Confer | Chief Financial Officer | A | +341,750 deriv. | — |
| 2021-09-28 | Hermant Kumar | Chief Mfgr & Tech Officer | A | +400,000 deriv. | — |
| 2021-09-28 | Mark Stanley Berger | Chief Medical Officer | A | +550,000 deriv. | — |
| 2021-06-25 | Brent M Longnecker | Director | A | +32,376 deriv. | — |
| 2021-06-25 | William R Wilson Jr. | Director | A | +32,376 deriv. | — |
| 2021-06-25 | Toscano Jose Antonio Moreno | Director | A | +32,376 deriv. | — |
| 2021-04-07 | Brent M Longnecker | Director | Buy | +15,000 | +$62.25K |
| 2021-03-23 | Ryan M. Confer | Chief Financial Officer | A | +235,000 deriv. | — |
| 2021-03-23 | John Rodney Varner | President & CEO | A | +460,000 deriv. | — |
| 2021-03-23 | Catherine M Vaczy | EVP GC Chief Strategy Officer | A | +200,000 deriv. | — |
| 2021-03-23 | Michael Thomas Redman | EVP & Chief Operating Officer | A | +200,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ryan M. Confer | President, CEO and CFO | 1,651 | $2.92K |
| Mark Stanley Berger | Chief Medical Officer | 986 | $1.74K |
| Brent M Longnecker | Director | 416 | $736 |
| Toscano Jose Antonio Moreno | Director | 416 | $736 |
| William R Wilson Jr. | Director | 416 | $736 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GNPX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.